Beyond Air (NASDAQ:XAIR) vs. Coloplast A/S (OTCMKTS:CLPBY) Head-To-Head Survey

Coloplast A/S (OTCMKTS:CLPBY) and Beyond Air (NASDAQ:XAIR) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings and risk.

Earnings & Valuation

This table compares Coloplast A/S and Beyond Air”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coloplast A/S	$4.13 billion	3.52	$538.49 million	$0.19	34.00
Beyond Air	$7.68 million	0.36	-$33.25 million	($68.40)	-0.04

Coloplast A/S has higher revenue and earnings than Beyond Air. Beyond Air is trading at a lower price-to-earnings ratio than Coloplast A/S, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Coloplast A/S and Beyond Air’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Coloplast A/S	9.68%	39.27%	11.54%
Beyond Air	-435.71%	-440.26%	-98.50%

Insider and Institutional Ownership

31.5% of Beyond Air shares are held by institutional investors. 10.0% of Beyond Air shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Risk and Volatility

Coloplast A/S has a beta of 0.16, suggesting that its stock price is 84% less volatile than the S&P 500. Comparatively, Beyond Air has a beta of 0.13, suggesting that its stock price is 87% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Coloplast A/S and Beyond Air, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coloplast A/S	1	1	0	1	2.33
Beyond Air	1	0	3	0	2.50

Beyond Air has a consensus target price of $105.00, suggesting a potential upside of 3,584.21%. Given Beyond Air’s stronger consensus rating and higher probable upside, analysts plainly believe Beyond Air is more favorable than Coloplast A/S.

Summary

Coloplast A/S beats Beyond Air on 10 of the 15 factors compared between the two stocks.

About Coloplast A/S

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. The company was founded in 1954 and is headquartered in Humlebæk, Denmark.

About Beyond Air

Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.